{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:02:40Z","timestamp":1793714560035,"version":"4.6.1"},"reference-count":37,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,7,15]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres. Outcomes included relapse-free survival (RFS), MRI activity-free survival (MFS), progression-free survival (PFS) and no evidence of disease activity (NEDA-3). We assessed 6-month confirmed Expanded Disability Status Scale (EDSS) score progression or improvement compared with pre-treatment. Treatment-related mortality (TRM) was defined as death from any cause within 100 days post-autologous graft reinfusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>364 pwMS were included (median age 40 years; 58% female). Of these, 271 pwMS had adequate neurological follow-up data: 168 (62%) had relapsing-remitting MS (pwRRMS) and 103 (38%) had progressive MS (pwPMS). Median disease duration from symptom onset was 10 years (IQR 6\u201314), EDSS 6 (IQR 4.0\u20136.5) and follow-up from AHSCT 46 months. At 2 and 5 years from AHSCT, RFS was 94.6% and 88.6%; MFS 93.1% and 80.1%; PFS 83.5% and 62.4%; NEDA-3 72.3% and 46.2%. pwRRMS had significantly higher rates of PFS (p=0.007) and NEDA-3 (p=0.001) than pwPMS. RRMS was a predictor of EDSS improvement, whose prevalence was 24.2% at 2 years and 20.4% at 5 years. TRM was 1.4% (n=5\/364).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this cohort with high EDSS at baseline and including pwPMS, AHSCT led to durable remission of inflammatory activity and stabilisation or improvement of neurological disability, particularly in pwRRMS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2025-336755","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:32:34Z","timestamp":1757093554000},"page":"jnnp-2025-336755","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-1218","authenticated-orcid":false,"given":"Paolo Antonio","family":"Muraro","sequence":"first","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College, London, UK"},{"name":"Neurology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Matteis","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College, London, UK"},{"name":"Neurology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Brittain","sequence":"additional","affiliation":[{"name":"Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust and NIHR Sheffield Biomedical Research Centre, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-7067","authenticated-orcid":false,"given":"Alice","family":"Mariottini","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College, London, UK"},{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0414-1225","authenticated-orcid":false,"given":"Richard","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College, London, UK"},{"name":"Neurology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Silber","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Haematology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"NIHR (National Institute for Health and Research) University College London Hospitals Biomedical Research Centre, London, UK"},{"name":"Queen Square MS Centre, UCL Queen Square Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lee","sequence":"additional","affiliation":[{"name":"British Society of Blood and Marrow Transplantation and Cellular Therapy, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pearce","sequence":"additional","affiliation":[{"name":"British Society of Blood and Marrow Transplantation and Cellular Therapy, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-104X","authenticated-orcid":false,"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[{"name":"University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[{"name":"University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Paul","sequence":"additional","affiliation":[{"name":"British Society of Blood and Marrow Transplantation and Cellular Therapy, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Snowden","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Sharrack","sequence":"additional","affiliation":[{"name":"Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK"},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust and NIHR Sheffield Biomedical Research Centre, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2025090510201492000_jnnp-2025-336755v1.1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2025090510201492000_jnnp-2025-336755v1.2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.adg7489","article-title":"Resetting tolerance in autoimmune disease","volume":"380","author":"Muraro","year":"2023","journal-title":"Science"},{"key":"2025090510201492000_jnnp-2025-336755v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.81"},{"key":"2025090510201492000_jnnp-2025-336755v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.014"},{"key":"2025090510201492000_jnnp-2025-336755v1.5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2025090510201492000_jnnp-2025-336755v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0684-0"},{"key":"2025090510201492000_jnnp-2025-336755v1.8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.htct.2020.03.002","article-title":"A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn\u2019s disease. Position paper of the Brazilian Society of Bone Marrow Transplantation","volume":"43","author":"Oliveira","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"key":"2025090510201492000_jnnp-2025-336755v1.9","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004228"},{"key":"2025090510201492000_jnnp-2025-336755v1.10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516645670"},{"key":"2025090510201492000_jnnp-2025-336755v1.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001329"},{"key":"2025090510201492000_jnnp-2025-336755v1.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743"},{"key":"2025090510201492000_jnnp-2025-336755v1.14","doi-asserted-by":"crossref","unstructured":"Alexander T , Sharrack B , Rovira M , et al . Autoimmune Disease . The EBMT Handbook: Springer, 2024:825\u201336.","DOI":"10.1007\/978-3-031-44080-9_92"},{"key":"2025090510201492000_jnnp-2025-336755v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"2025090510201492000_jnnp-2025-336755v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025090510201492000_jnnp-2025-336755v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703"},{"key":"2025090510201492000_jnnp-2025-336755v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032"},{"key":"2025090510201492000_jnnp-2025-336755v1.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.907"},{"key":"2025090510201492000_jnnp-2025-336755v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050605"},{"key":"2025090510201492000_jnnp-2025-336755v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.185"},{"key":"2025090510201492000_jnnp-2025-336755v1.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083582","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial","volume":"14","author":"Brittain","year":"2024","journal-title":"BMJ Open"},{"key":"2025090510201492000_jnnp-2025-336755v1.23","unstructured":"BEAM\/atg or cyclophosphamide\/atg as conditioning regimen in autologous transplantation for multiple sclerosis: a retrospective analysis of the ebmt autoimmune diseases working party. 50th Annual Meeting of the EBMT; 2024"},{"key":"2025090510201492000_jnnp-2025-336755v1.24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.26","doi-asserted-by":"crossref","unstructured":"Kazmi M , Muraro PA , Mehra V , et al . Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT). Br J Haematol 2025. doi:10.1111\/bjh.20199","DOI":"10.1111\/bjh.20199"},{"key":"2025090510201492000_jnnp-2025-336755v1.27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1352458520936236","article-title":"Prevalence of disability improvement as a potential outcome for multiple sclerosis trials","volume":"27","author":"Signori","year":"2021","journal-title":"Mult Scler"},{"key":"2025090510201492000_jnnp-2025-336755v1.28","first-page":"e1215","article-title":"Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis","volume":"96","author":"Boffa","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025090510201492000_jnnp-2025-336755v1.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331864"},{"key":"2025090510201492000_jnnp-2025-336755v1.30","first-page":"e890","article-title":"Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025090510201492000_jnnp-2025-336755v1.31","doi-asserted-by":"crossref","unstructured":"Noui Y , Zjukovskaja C , Silfverberg T , et al . Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis. J Neurol Neurosurg Psychiatry 2025. doi:10.1136\/jnnp-2024-335512","DOI":"10.1136\/jnnp-2024-335512"},{"key":"2025090510201492000_jnnp-2025-336755v1.32","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332790"},{"key":"2025090510201492000_jnnp-2025-336755v1.34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study","volume":"98","author":"Muraro","year":"2025","journal-title":"Ann Neurol"},{"key":"2025090510201492000_jnnp-2025-336755v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.305"},{"key":"2025090510201492000_jnnp-2025-336755v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102404"},{"key":"2025090510201492000_jnnp-2025-336755v1.37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-323-90242-7.00007-9","article-title":"Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases","volume":"202","author":"Hughes","year":"2024","journal-title":"Handb Clin Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-336755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:32:38Z","timestamp":1757093558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-336755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":37,"alternative-id":["10.1136\/jnnp-2025-336755"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-336755","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}